Millions of people across the United States live with schizophrenia, and in Northwest Arkansas, UAMS aims to join in aiding ...

The primary goal of the trial is to measure the decrease in the Positive and Negative Syndrome Scale from baseline.

In particular, the results from the late-stage Arise trial demonstrate a “noteworthy improvement” for most schizophrenia patients and reinforce the drug’s tolerable safety profile ...

Schizophrenia drug Cobenfy, a key component in Bristol Myers Squibb’s plan to navigate a transition period of major loss of exclusivity, has hit a phase 3 setback. Cobenfy as an adjunctive ...

In September 2024, the FDA approved Cobenfy, an oral medication for schizophrenia in adults. Data from the EMERGENT clinical program supported the FDA approval of Cobenfy. In Phase 3 EMERGENT-2 ...

"BMS’ schizophrenia therapy fails in Phase III trial as an adjunctive treatment" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this ...

US-based pharmaceutical company Bristol Myers Squibb (BMS) has reported topline outcomes from the Phase III ARISE trial of Cobenfy as an adjunctive treatment to atypical antipsychotics for ...

Bristol Myers Squibb has shared results from its Phase III ARISE trial evaluating Cobenfy (xanomeline and trospium chloride) as an add on therapy to atypical antipsychotics in adults with inadequately ...

Bris­tol My­ers Squibb’s at­tempt to turn Coben­fy in­to a megablock­buster neu­ro­science drug ran in­to a stum­bling block Tues­day af­ter­noon.

"Adjunctive treatment trials in schizophrenia present significant clinical ... Bristol Myers Squibb will complete a full evaluation of the Phase 3 trial data and intends to present detailed ...

SRM Institute of Science and Technology (SRMIST) has started the SRM Joint Engineering Entrance Examination (SRMJEEE) 2025 slot booking for phase 1. Candidates can select their preferred exam ...

During the stable phase, it is particularly important to teach the patient and family to recognize prodromal symptoms or early signs of exacerbation. During prodromal episodes, early intervention ...